# Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

> **NCT05499416** · PHASE4 · WITHDRAWN · sponsor: **Innovaderm Research Inc.**

## Conditions studied

- Psoriasis Vulgaris
- Active Psoriatic Arthritis

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT05499416
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01
- **Primary completion:** 2023-09
- **Final completion:** 2024-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2023-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05499416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05499416, "Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05499416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*